Intervention not reported
Daclizumab plus glucocorticosteroids (3 RCTs; 1045 participants) · adults undergoing liver transplantation
It is very uncertain whether the intervention changes daclizumab plus glucocorticosteroids (3 RCTs; 1045 participants) (very low certainty).
1 finding from 1 review
HR 1.26 [0.66, 2.42]
Studies not reported
Very low
Intervention not reported
Daclizumab (3 RCTs; 420 participants) · adults undergoing liver transplantation
It is very uncertain whether the intervention changes daclizumab (3 RCTs; 420 participants) (very low certainty).
1 finding from 1 review
OR 0.62 [0.38, 1.02]
Studies not reported
Very low
Intervention not reported
Basiliximab plus glucocorticosteroids (1 RCT; 147 participants) · adults undergoing liver transplantation
It is very uncertain whether the intervention changes basiliximab plus glucocorticosteroids (1 RCT; 147 participants) (very low certainty).
1 finding from 1 review
OR 1.21 [0.52, 2.72]
Studies not reported
Very low
Intervention not reported
Daclizumab plus glucocorticosteroids (2 RCTs; 728 participants) · adults undergoing liver transplantation
It is very uncertain whether the intervention changes daclizumab plus glucocorticosteroids (2 RCTs; 728 participants) (very low certainty).
1 finding from 1 review
OR 0.94 [0.67, 1.31]
Studies not reported
Very low
Intervention not reported
Basiliximab plus glucocorticosteroids (3 RCTs; 627 participants) · adults undergoing liver transplantation
It is very uncertain whether the intervention changes basiliximab plus glucocorticosteroids (3 RCTs; 627 participants) (very low certainty).
1 finding from 1 review
HR 0.72 [0.42, 1.15]
Studies not reported
Very low
Intervention not reported
Anti‐thymocyte globulin plus glucocorticosteroids (3 RCTs; 152 participants) · adults undergoing liver transplantation
It is very uncertain whether the intervention changes anti‐thymocyte globulin plus glucocorticosteroids (3 RCTs; 152… (very low certainty).
1 finding from 1 review
HR 1.72 [0.7, 4.28]
Studies not reported
Very low
Intervention not reported
Basiliximab (2 RCTs; 131 participants) · adults undergoing liver transplantation
The intervention may leads to lower basiliximab (2 RCTs; 131 participants) (low certainty).
1 finding from 1 review
HR 0.53 [0.31, 0.93]
Studies not reported
Low
Intervention not reported
Daclizumab plus glucocorticosteroids (5 RCTs; 1142 participants) · adults undergoing liver transplantation
It is very uncertain whether the intervention changes daclizumab plus glucocorticosteroids (5 RCTs; 1142 participants) (very low certainty).
1 finding from 1 review
HR 1.33 [0.78, 2.43]
Studies not reported
Very low
Intervention not reported
Anti‐thymocyte globulin (2 RCTs; 194 participants) · adults undergoing liver transplantation
It is very uncertain whether the intervention changes anti‐thymocyte globulin (2 RCTs; 194 participants) (very low certainty).
1 finding from 1 review
HR 1.2 [0.58, 2.59]
Studies not reported
Very low
Intervention not reported
Daclizumab (2 RCTs; 350 participants) · adults undergoing liver transplantation
It is very uncertain whether the intervention changes daclizumab (2 RCTs; 350 participants) (very low certainty).
1 finding from 1 review
HR 1.29 [0.6, 3.06]
Studies not reported
Very low
Intervention not reported
No active intervention (1 RCT; 45 participants) · adults undergoing liver transplantation
It is very uncertain whether the intervention changes no active intervention (1 RCT; 45 participants) (very low certainty).
1 finding from 1 review
HR 0.75 [0.18, 3.13]
Studies not reported
Very low
Intervention not reported
All‐cause mortality: up to 3 months' · participants with alcoholic hepatitis at high risk of mortality and morbidity
It is very uncertain whether the intervention changes all‐cause mortality: up to 3 months' (very low certainty).
1 finding from 1 review
Intervention not reported
Health‐related quality of life: up to 3 months ( · participants with alcoholic hepatitis at high risk of mortality and morbidity
The intervention showed no clear difference in health‐related quality of life: up to 3 months ( (low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events during treatment · participants with alcoholic hepatitis at high risk of mortality and morbidity
It is very uncertain whether the intervention changes serious adverse events during treatment (very low certainty).
1 finding from 1 review
Intervention not reported
Liver‐related mortality: up to 3 months' · participants with alcoholic hepatitis at high risk of mortality and morbidity
It is very uncertain whether the intervention changes liver‐related mortality: up to 3 months' (very low certainty).
1 finding from 1 review
Intervention not reported
Participants with any complication: up to 3 months following randomisation · participants with alcoholic hepatitis at high risk of mortality and morbidity
It is very uncertain whether the intervention changes participants with any complication: up to 3 months following… (very low certainty).
1 finding from 1 review
Intervention not reported
Participants with non‐serious adverse events: up to 3 months' · participants with alcoholic hepatitis at high risk of mortality and morbidity
It is very uncertain whether the intervention changes participants with non‐serious adverse events: up to 3 months' (very low certainty).
1 finding from 1 review
All‐cause mortality · cirrhotic participants with large ascites treated by paracentesis
It is very uncertain whether plasma expanders changes all‐cause mortality compared with no plasma expanders (very low certainty).
1 finding from 1 review
Refractory ascites · cirrhotic participants with large ascites treated by paracentesis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Incidence of renal impairment · cirrhotic participants with large ascites treated by paracentesis
It is very uncertain whether other plasma expanders changes renal impairment compared with albumin (very low certainty).
1 finding from 1 review